The neurotoxins produced by Clostridium botulinum are the most lethal substances known. Botulinum toxin can kill a mouse at a level of 5 to 10 pg, or approximately 30 attomol per mouse, injected intraperitoneally. In order to provide protection from intoxication with this highly lethal protein, especially to individuals potentially exposed to this toxin environmentally (e.g., horses exposed to toxin in feed stored under anaerobic conditions and laboratory workers in laboratories studying Clostridium botulinum), toxoid preparations consisting of formalinized toxins and immunization protocols have been developed, and these preparations afford a considerable degree of protection (8) . Evaluation of these protocols, as well as potential improvements in these protocols by use of engineered vaccines with high antigenicity but no toxicity, requires the sensitive measurement of levels of antibody against intact toxins.
When development of active immunity by toxoid immunization is impractical, i.e., for individuals intoxicated by contaminated food, passive immunization has proven to be an effective treatment. For adults ill with botulinum toxin poisoning, this is provided by injection of xenogeneic antisera (typically from horses). Because infants afflicted with the disease of infant botulism always recover and the risk of serum sickness is significant, a protocol was recently initiated for the treatment of infant botulism by the injection of human gamma globulin isolated from individuals actively immunized with toxoid (10) .
Distinct from the protection of individuals from exposure to toxin, the use of highly diluted C. botulinum toxin preparations for the localized treatment of spastic disorders has proven to be a highly effective remedy for these problems (5, 6) . In light of the fact that these disorders are chronic and lifelong administration of these toxin preparations is required, the recent suggestion that resistance to toxin may occur as a result of gradual immunization during treatment gives rise to the concern that the ability to use this highly effective remedy will be limited (7) .
For these reasons, the accurate and sensitive measurement of antibody against botulinum toxin is an important component in the protection against, study of, and therapeutic use of these toxins.
The accepted standard for these measurements is the mouse neutralization test, in which toxin preparations are mixed with diluted antisera and then injected into a mouse. The decrease in toxicity at a given antiserum dilution is the antiserum titer, compared with that of standard antiserum preparations (11) . Because this is such a tedious, expensive, and time-consuming test, efforts have been made to find an alternative approach for titer determination. Enzyme-linked immunosorbent assay (ELISA) methods with toxin-coated plates can measure titers, but the values obtained do not correlate closely with mouse neutralization test measurements (12) .
We recently developed an amplified immunoassay for botulinum toxin whose sensitivity matched the sensitivity of the mouse bioassay (1, 3, 4, 9) . We were able to demonstrate that titers of human and horse antisera could be measured by competition of binding with the labeled complexes (2) .
In one modification of the toxin immunoassay, we used capture of fluoresceinated antibodies onto an antifluorescein matrix to bind specific complexes (3) . It occurred to us that the complexes of fluoresceinated and enzyme-labeled horse antibodies bound to toxin could be eluted from the antifluorescein capture plate with fluorescein and that if human or any other antibodies except horse antibodies were bound to these complexes they could be bound to a matrix of anti-specific immunoglobulin G (IgG; e.g., anti-human IgG) after elution.
In this work, we demonstrate that this approach is a useful way to measure antibodies to botulinum toxins A, B, and E. Using chicken antibodies raised against specific toxoids and purified by affinity chromatography (1) and sera from human subjects either immunized with toxoid or treated with toxin, we were able to demonstrate that this approach results in a specific, sensitive assay for antibody to botulinum toxin. The assay can be performed with undiluted serum with high specificity and sensitivity and without background interference due to nonspecific binding.
(The technology described in this report is protected under U.S. patent 4,668,621 and foreign analogs and other patent applications pending.)
MATERIALS AND METHODS
ELISA-ELCA for botulinum toxin. In previous reports, we have described the details of the development of the ELISA and the enzyme-linked coagulation assay (ELCA) (1, 3, 4, 9) .
In the ELISA portion of this assay, conjugates of affinity-purified or latecourse, high-titer antibody for botulinum toxin with the coagulation-activating snake venom enzyme Russell's viper venom factor X activator (RVV-XA) are prepared. These conjugates are used to prepare detectable complexes with solid phases coated with capture antibody (4) or in solution phase with affinity-purified chicken antitoxin antibody or biotinylated antibody (1) or with fluoresceinated horse antibody (3). When solution-phase complexes are formed, capture of the complex with appropriate capture matrices such as anti-chicken IgY for chicken antibodies (1) (IgY is the common term used to describe the IgG fraction which is isolated from egg yolks), avidin, or streptavidin for biotinylated antibody (1) and antifluorescein for fluoresceinated antibodies (3) is an effective method for isolating and measuring the complexes. The antibodies used in these previous studies were from horses immunized at the Fort Detrick (Frederick, Md.) large animal facility and from chickens maintained at the Bowman Gray School of Medicine. Affinity-purified antibodies were obtained by coupling pure neurotoxins to agarose columns and isolating the antibodies on these toxin columns.
Once the complexes are bound to a microtiter plate, they are measured by a solid-phase coagulation assay which we have named ELCA. In this assay, coagulation is measured by the simultaneous production of solution-phase enzymelabeled fibrin and solid-phase fibrin, which results in the deposition of enzymelabeled fibrin onto the solid phase due to the action of thrombin. The thrombin is generated by the hydrolysis of the proenzyme factor X by the RVV-XA present in the immune complex, followed by active factor X (Xa) hydrolysis of the proenzyme prothrombin to thrombin and the subsequent hydrolysis of labeled and solid-phase fibrinogen in the ELCA system.
Combining the use of affinity-purified antibody or hyperimmune horse antibodies with the cascade amplification available by using RVV-XA as the labeling enzyme and the solid-phase detection of enzyme-labeled fibrin, sensitivities of detection of neurotoxin comparable to those of mouse toxicity tests (less than 10 pg/ml) have been obtained in the ELISA-ELCA (1, 3, 4) . The ELISA-ELCA can be applied to the measurement of toxins from food homogenates (9) . A modification of the assay has also been described (2) . This modification allows for the measurement of antibodies by competition with the labeled antibodies (2) .
The reagents developed in those studies were used in the current work, with the following modifications.
(i) Human sera. Human sera from subjects immunized with pentavalent toxoid were obtained from the Centers for Disease Control and Prevention. The sera were principally obtained from subjects who contributed sera used in the preparation of the human antibody preparation currently being used for the treatment of infant botulism (botulism immune globulin) and control subjects who had not been so immunized and who did not have measurable antibody by the mouse neutralization test. Sera were also obtained from subjects being treated for spastic disorders by injection of botulinum toxin A (BOTOX) at the Center for Voice Disorders, Bowman Gray School of Medicine, and North Carolina Baptist Hospitals.
(ii) Horse antisera. The horse antisera used for the preparation of labeled anti-botulinum toxin were from animals immunized for 3 years with preparations of toxoids from individual toxin serotypes, either A, B, or E in this case, and maintained in the Fort Detrick large animal facility. These antisera have been characterized for their use in immunoassays of neurotoxin by ELISA-ELCA (3). The immunoglobulin fraction was obtained from these antisera by precipitation in 40% saturated ammonium sulfate. An (FabЈ) 2 preparation was made from these precipitates by digestion of the immunoglobulin preparation with 2% (by weight) pepsin in 0.1 M acetate buffer (pH 4.0) overnight at room temperature. The (FabЈ) 2 fraction was purified on a column (1 by 50 cm) of Sephacryl S200. This fraction was labeled as described previously (3) with fluorescein maleimide and RVV-XA-maleimide derivatives. The derivatized fractions were used without further purification. It should be noted that the antibody fraction was not affinity purified, nor was it toxin specific. The toxoids used for immunization were from toxin complex rather than pure neurotoxin. The specificity of the assay therefore derives from the use of pure toxin in the complex-specific immunoassay.
(iii) Monoclonal antibodies. Monoclonal antibodies were raised against toxins A and B as described previously (3) . IgG fractions of mouse ascites were purified by ammonium sulfate precipitation and QAE-agarose chromatography as described previously (3). Monoclonal antibodies were not digested with pepsin before use, but were reduced with 5 mM dithiothreitol and derivatized with fluorescein maleimide.
(iv) Antifluorescein antibodies. Antifluorescein antibodies were from goats immunized with fluorescein isothiocyanate-conjugated keyhole limpet hemocyanin injected subcutaneously in Freund's complete adjuvant and boosted with fluorescein isothiocyanate-conjugated bovine serum albumin injected intramuscularly in saline. Sera were purified by binding to columns of fluoresceinamine coupled to Aminolink columns (Pierce Chemical Co., Rockford, Ill.) and were eluted with 5% acetic acid in water. Eluted antibodies were neutralized with phosphate buffer, precipitated with 40% saturated ammonium sulfate, dialyzed against phosphate-buffered saline, concentrated against an equal volume of glycerol, and then stored at Ϫ20ЊC. Antifluorescein beads were prepared by coupling the purified antibodies to Emphase gel (Pierce Chemical Co.) according to the manufacturer's instructions.
Protocol for the measurement of antibody titer using affinity elution. (i) Microtiter plate protocol. Mixtures of fluoresceinated horse polyclonal or mouse monoclonal antibody and RVV-XA-labeled horse antibody with various dilutions of either chicken immunoglobulin preparations or human serum were mixed with toxins and incubated in solution phase for 1 to 48 h in casein dilution solution (0.1 M imidazole-HCl, 0.5 M NaCl, 0.5% Triton X-100, 10 mg of casein per ml). The complexes were then bound to a microtiter plate coated with antifluorescein antibody for 1 h at 37ЊC or 16 to 24 h at 4ЊC, depending on the experiment. After binding, the plate was washed with saline by using the Elcawash microtiter plate washer (Elcatech, Inc., Winston-Salem, N.C.) and was soaked with calcium-gelatin wash solution (0.025 M imidazole-HCl, 0.15 M NaCl, 3 mM CaCl 2 , 10 mg of bovine gelatin per ml [pH 7.6]) for 10 min at room temperature. The plates were then washed with saline and incubated with 1 mM fluorescein in casein dilution solution containing 1 mg of nonspecific horse IgG per ml for 1 h at 37ЊC unless stated otherwise. The solution in the microtiter well was then transferred to a plate coated with either anti-chicken IgY or anti-human IgG, depending on the experiment, and the plate was incubated at 37ЊC for 60 min. The plate was then washed with saline and soaked for three 5-min intervals in calcium-gelatin wash solution and then assayed by ELCA as described previously (1, 3, 4, 9) . The protocol is presented in Fig. 1 for human antibody. It was identical for chicken antibody, except that the eluted complex was bound to anti-chicken IgY.
(ii) Assay with antifluorescein gel. A pipet tip was loosely plugged with cotton. A suspension of 50 l of antifluorescein beads was added to the mixture of 500 l of fluoresceinated horse antibody, RVV-XA-horse antibody, toxin at concentrations of 0, 2, 20, and 200 ng/ml, and 1 g of affinity-purified chicken antibody per ml. After incubation overnight at 4ЊC, the mixture was collected in the plugged pipet tips and was washed thoroughly with buffer. Aliquots of 400 l of 1 mM fluorescein in casein dilution buffer were passed through the column rapidly (this first elution took approximately 10 min; during this time, fluorescein was present in the columns and was effective in eluting complex, which dissociated rapidly), and the eluates were collected in tubes. The columns were then incubated for an additional 30 min at room temperature, and another 400 l of 1 mM fluorescein was passed through and collected. The columns were then incubated for an additional 150 min and were washed through with another 400 l of 1 mM fluorescein. The eluates from each series were then serially diluted in twofold increments onto a plate of goat anti-chicken IgY in casein, incubated, washed, and assayed.
antibody, and affinity-purified chicken antibody at a concentration of 100 ng/ml was added. This mixture was allowed to incubate overnight and was then bound to plates of goat antifluorescein and goat anti-chicken IgY antibody. The goat antichicken IgY plate had a limit of detection of 40 to 120 pg of toxin per ml when both fluoresceinated horse antibody and affinity-purified chicken antibody were present in the complex. Before the assay the goat antifluorescein plate was treated with fluorescein concentrations of 0, 0.12, 0.37, 1.1, 3.3, and 10 mM for 20 h, and then the eluate was transferred to a plate of goat anti-chicken IgY, the plate was incubated for 60 min at 37ЊC, and both plates (the antifluorescein and goat anti-chicken IgY plates) were assayed. The detection limits of toxin on the two plates (antifluorescein and anti-chicken IgY plates) are presented in Table 1 . When the antifluorescein plate was not incubated with fluorescein, the detection limit of toxin was 43 pg/ml. After elution with fluorescein concentrations of 0.12 to 10 mM, the detection limit was significantly reduced on the antifluorescein plate, suggesting elution of the complex. Some of the complexes that eluted from the antifluorescein plates were able to bind to the anti-chicken IgY plate, as indicated by the presence of measurable complex bound to the plate and the absence of such a complex when fluorescein was not used to elute the complex. Under these conditions, the limit of detection appeared to be about 1 ng of toxin (per ml) present in the complex eluted from the antifluorescein plate.
Assay specificity, chicken antibodies, and fluoresceinated monoclonal and polyclonal antibody capture. Using the affinitypurified chicken antibodies, we used reaction mixtures consisting of fluoresceinated polyclonal (horse) and fluoresceinated monoclonal (mouse) antibodies for capture and RVV-XAlabeled polyclonal (horse) antibody. Affinity-purified chicken antibodies specific for either the A or the B toxin were serially diluted into the antibody mixture, and toxin was added to a final concentration of 10 ng/ml. The mixture was incubated for 3 h at 37ЊC on an antifluorescein capture plate, and the plate was then washed and eluted with fluorescein overnight at 4ЊC. The eluate was transferred to a plate of goat anti-chicken IgY, washed, and assayed. The results are given in Table 2 . The specificities of the reactions with toxins A and B were demonstrated with these affinity-purified antibodies, in that no reaction was found with the chicken antibodies against the heterologous antigen (either toxin A or toxin B). In this experiment the sensitivity of detection reached a limit of 3.7 ng/ml with highly diluted fluoresceinated horse antibody. Fluoresceinated monoclonal antibodies yielded a less sensitive assay, but with equal specificity.
Detection of antibodies in crude preparations of chicken IgY. In order to evaluate the usefulness of the assay for measuring antibody titers in samples which contained specific antibody as a small fraction of the total immunoglobulin present, we used IgY fractions from egg yolks of chickens immunized with toxoids prepared from toxins A, B, and E. The results of this assay, expressed as relative dilutions, are presented in Table 3 . The antibody specificity was that of the toxoid antigen, and no antibody against the heterologous antigen was found within the range of dilutions tested.
Use of antifluorescein beads and time for elution of complex using added fluorescein. The binding of complex to a microtiter plate is limited by the capacity of the plate for absorption. A more effective approach for trapping complex is to bind the complex to solid-phase matrices such as columns or magnetic a The RVV-XA-antibody and toxin used had the same specificities as the fluoresceinated antibodies. Chicken antibodies were tested for reaction with either toxin A or B. Data are the limit of detection of the diluted chicken antibody under the given assay conditions. FL-MC, fluoresceinated monoclonal antibody; FL-PC, fluoresceinated polyclonal antibody; A, toxin A; B, toxin B.
b Values in parentheses are dilutions.
beads coated with antifluorescein, since the total surface area for absorption is much larger. This approach was used, as described in Materials and Methods. The results are presented in Table 4 . Most of the detectable antibody was eluted from the antifluorescein columns within 30 min. Additional antibody was eluted at 150 min, but comparing the dilutions of complex detectable at this elution time suggests that less than 20% of the eluted complex was eluted after 30 min of treatment, since subsequent treatment of the columns for up to 2.5 h did not add appreciably to the total amount of antibody eluate. No signal was detectable when toxin was absent from the reaction mixture. The optimal sensitivity of the assay for detection of antibody was found in this experiment to be at the highest concentration of toxin tested (i.e., 200 ng/ml). Similar results for the speed of elution were obtained in several experiments on microtiter plates, indicating that 30 to 60 min of fluorescein elution was optimal. The concentrations of toxin found to be optimal were different, however. The optimal concentration for toxin A was 10 ng/ml, that for toxin B was 100 ng/ml, and that for toxin E was 20 ng/ml.
Optimization of conditions for antibody assay. In the experiment whose results are presented in Table 4 , we used a single concentration of each specific antibody (i.e., 1 g/ml). In other experiments, in which the antibodies were serially diluted, we found that the optimal concentrations of toxins A, B, and E for the detection of diluted specific chicken antibody were 10, 100, and 20 ng/ml, respectively. Using these concentrations of toxins, we optimized the dilutions of fluoresceinated antibody and RVV-XA-antibody to yield maximal sensitivity of antibody detection. The results of the assay of affinity-purified chicken antibodies are presented in Fig. 2 . Antibody to toxin A was measurable at 1 ng/ml, that to toxin B was measurable at 0.4 ng/ml, and that to toxin E was measurable at 4 ng/ml.
Test of human antibodies and individuals immunized with toxoid.
Using the fluorescein-antibody and RVV-XA-antibody dilutions of Fig. 2 , we tested human antisera against botulinum toxin obtained from individuals immunized with multivalent toxoid. Sera from nonimmunized individuals gave no detectable antibody in this series when they were tested undiluted. Table 5 gives the results for three such serum samples tested against toxins A, B, and E.
In these assays, titers as great as 8,100 to 24,300 were measurable in the sera of selected subjects. The wide variability of response to the different toxins present in the toxoid preparation is indicated by the low titer of antibody to toxin E in subject 1. Note that under these conditions the assay for affinity-purified chicken antibody to toxin E was less sensitive (detection limit, 4 ng/ml) than that to toxin A (1 ng/ml) or B (0.4 ng/ml) (Fig. 2) .
Antibody in BOTOX-treated patients. A total of 65 serum samples from BOTOX-treated patients were tested for their reactivities against toxin A (the administered form) and toxin B (antisera against toxin B are not reactive with the administered toxin). Of the 65 samples, 4 were reactive with toxin A, and 2 of these were reactive with toxin B as well. Eighteen serum samples showed reactivity with toxin B. Results for five of the serum samples which were reactive with either toxin A or toxin B are presented in Table 6 .
With serum diluted serially twofold, the assay could discriminate between three individuals who produce antibody to toxin B and two who produce antibody to toxin A. As controls, assays were performed with sera diluted 1:1 by using reaction mixtures to which no toxin was added. In all cases, no detectable antibody was measured by this technique in the absence of toxin. For the two samples showing reactivity with toxin A (samples 4 and 5), sample 5 showed a reproducible, very low titer of antibody by this protocol. Sample 4, which was from a subject who was receiving very high doses of BOTOX for therapeutic reasons, was producing measurable amounts of antibody to toxin A. The three subjects producing antibody to toxin B showed very different titers. None of these samples had measurable antibody to toxin E.
DISCUSSION
In this work, we have demonstrated an affinity chromatography technique which was useful in measuring antibodies to C. botulinum neurotoxins. In this approach three distinct antibody species are bound to toxin in solution phase; one is labeled with the hapten fluorescein, one is labeled with enzyme (in this case, RVV-XA), and one is unlabeled but is from a species distinct from the species that is the source of the la- a The RVV-XA-antibody and toxin used had the same specificities as the fluoresceinated antibodies. Chicken antibodies were from concentrated antibody preparations prepared by ion-exchange chromatography, in which the IgY concentrations were approximately 50 to 100 mg/ml. Dilutions of 1:100, which were the highest concentrations tested, represent 0.5 to 1 mg of IgY per ml. The maximal dilution of this preparation which gave a measurable signal is indicated. a Results indicate the dilution of eluted complex which was measurable after binding to an anti-chicken IgY plate. Affinity-purified chicken antibody at 1 g/ml was added to the reaction mixture (see Materials and Methods). Ab, antibody. beled antibodies. The complex is captured on a matrix of antihapten, washed, and then eluted under nondenaturing conditions, with excess hapten added in solution. The eluted complex can be bound to a second matrix of anti-immunoglobulin, permitting the measurement of the titer of the unlabeled antibody.
The assay was found to be specific and sensitive for the measurement of monovalent, toxin-specific chicken antibodies purified either by affinity chromatography or by isolating IgY fractions from egg yolks. Capture on either microtiter plates or column matrices coated with antifluorescein was equivalent, and either fluoresceinated polyclonal antisera or monoclonal antibodies were useful for the isolation of complexes.
By the same protocol but with capture on anti-human IgG rather than anti-chicken IgY, it was possible to measure human antibodies against neurotoxins A, B, and E present in sera from individuals immunized with pentavalent toxoid. Titers as great as 24,300 (fold dilution) were measurable against toxins A and B, and titers up to 2,700 were measurable against toxin E. It should be noted that in mouse neutralization assays for these sera, antibodies in sera diluted up to 2,000-fold (toxin A) and 800-fold (toxin B) were detectable when 0.5 ml of diluted antisera was used. In these assays, 100 l was used for the hapten elution assay, while the mouse neutralization assay used 500 to 1,000 l, and the dilutions of sera in which antibodies were measurable were more than 10-fold greater.
For subjects not deliberately immunized with toxoid but exposed to C. botulinum toxin type A in the form of the therapeutically administered BOTOX preparation, we found that only 2 of 64 subjects had measurable antibody to type A neurotoxin and no reactivity with type B neurotoxin. In only one subject was there a significant titer, i.e., measurable antibody at a dilution greater than 1:10. For 18 subjects there was measurable antibody to toxin B, even though these subjects had no history of exposure to toxin B. In one subject (Table 6 ) the titer against toxin B reached dilutions higher than 256-fold. Controls without toxin showed no reaction, and there was no reaction with toxin A or E under the assay conditions in which these sera were tested.
We note from the above that this assay has a wide dynamic range. Antibodies are detectable from pentavalent toxoid-immunized subjects at dilutions as great as 24,300-fold, but most undiluted sera have no detectable antibody to toxin A. Controls which are usable in this assay include toxin specificity (performing the assay without toxin or at various concentrations of toxin) and testing of antibody reactions with several toxin types. This latter control may be useful in isolated cases since some individuals may be immune to horse immunoglobulins or RVV-XA, which would result in artifactual binding of human antibody to the toxin-containing immune complex through epitopes other than those of the toxin.
The choice of fluorescein as a label for this assay was based on the fact that fluorescein completely fills an antigenic site (14) and that antifluorescein antibodies can vary widely in their affinity, but their dissociation rates are generally measurable in seconds to minutes (13) . It is therefore possible to rapidly dissociate most of the complex from the antifluorescein matrix with free fluorescein. Alternative hapten labels should have these properties in common with fluorescein. In one experiment with biotinylated antibody and streptavidin binding, it was not possible to dissociate measurable complex by overnight elution in 1 mM biotin (data not shown).
In subsequent refinements, we will select as capture antibodies moderate-affinity monoclonal antibodies (13) or polyclonal antibodies that are rapidly eluted from hapten absorbents with haptens in solution. It should also be possible to perform several assays with the same sample by using several haptenlabeled-antibody species. In this case, a mixture of fluoresceinated, rhodamine-labeled, and Texas red-labeled antibodies against toxins A, B, and E could be added with the appropriate a Assay conditions were identical to those described for Table 5 ; the assays were performed on the same plates.
b See footnote a of Table 5 .
toxins and RVV-labeled antibodies, and the specific reactions could be selected by binding to separate antihapten absorbents. Also, anti-human IgG, IgA, or IgM absorbents could be used to measure complexes with the eluted antibodies. The amplification system that we have used to measure these complexes is the ELISA-ELCA. This has the specific advantage of being a very sensitive, colorimetric assay with a detection limit for labeled conjugates in the attomolar range. It is also the method that we used to develop the toxin immunoassay (1, 3, 4, 9) , so all the conjugates used in this antibody assay were available. Any other detection method would be usable with this hapten elution approach, provided that the hapten used for elution or the hapten-labeled antibody present in the immune complex and bound to the anti-human IgG did not interfere with detection. It should be possible to identify such haptens for every assay method one wishes to use.
